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 ABSTRACT 
 
Stratified medicine in paediatrics is increasingly becoming a reality, as our 
understanding of disease pathogenesis improves and novel treatment targets 
emerge. We have already seen some success in paediatrics in targeted 
therapies such as cystic fibrosis for specific CFTR (cystic fibrosis 
transmembrane conductance regulator) variants. With the increased speed and 
decreased cost of processing and analysing data from rare disease registries, 
we are increasingly able to use a systems biology approach (including ‘-omics’) 
to screen across populations for molecules and genes of interest. Improving 
our understanding of the molecular mechanisms underlying disease, and how 
to classify patients according to these will lead the way for targeted therapies 
for individual patients. This review article will summarise how ‘big data’ and the 
‘omics’ are being used and developed, and taking examples from paediatric 
renal medicine and rheumatology, demonstrate progress being made towards 
stratified medicine for children.  
 
 
  
INTRODUCTION 
 
Stratified medicine aims to define distinct patient subgroups based on 
increased understanding of the pathophysiology of disease, and ultimately, will 
enable tailoring of management and therapies to each individual patient. 
Precision medicine and personalised medicine are sometimes used 
interchangeably with stratified medicine but there are some subtle differences. 
Precision medicine, in addition to the above, encompasses the repeated 
monitoring of patients to enable fine-tuning of treatment to patient response.[1] 
Personalised medicine, in addition to biological stratification, takes into account 
patient choice and participation.[2] Currently we already clinically stratify 
patients, usually from observational criteria, in order to manage their conditions, 
but we are now becoming armed with a wealth of additional data that could 
provide us with more clarity and precision via a systems biology approach.[3] 
 
For certain diseases such as paediatric rare renal diseases and juvenile 
idiopathic arthritis, clinical research patient registries (e.g. RaDaR, the National 
Registry of Rare Kidney Diseases[4], British Society for Paediatric and 
Adolescent Rheumatology Biologics Registries[5,6] and Childhood Arthritis 
Prospective Study (CAPS)[7]) are well established in the UK. These have 
provided a bank of phenotypical data and biological samples for study of these 
disorders. With the increasing affordability and speed of processing these 
samples, and vast improvements in our ability to analyse this data, we are now 
well placed to further stratify our paediatric patients for targeted therapy. NHS 
England is aiming for improved diagnostics via personalised medicine by 2020, 
and for improved targeted therapies by 2025.[2] The 100,000 genomes project 
has been launched with the view of achieving these aims for rare disease and 
cancer.[8] Here, we aim to discuss broader progress in stratified medicine and 
how it will be particularly relevant to rare diseases in paediatrics.  
 
RARE DISEASES IN CHILDREN 
 
Rare disease in Europe is defined as having a prevalence of less than 50 in 
100,000 cases.[9] There are between 5000 to 8000 rare diseases[10], which 
affects between six to eight per cent of the population in total. Approximately 
75% of rare diseases affect children, and 30% of these children die by the age 
of five.[11] 80% of rare disease is thought to be genetic in origin, while the 
remaining conditions have varying aetiologies, for example, infection, toxins, 
autoimmunity, and certain cancers.   
 
Classification of rare disease currently is often observational, and does not 
necessarily reflect underlying biological mechanisms. For example, in nephrotic 
syndrome, current classification of disease is based on histology and patient 
responsiveness to steroids. This has limited utility in prognostication and in 
deciding appropriate therapeutic interventions for patients. With advances in 
systems biology approaches (the computational and mathematical modelling of 
complex biological systems, using a holistic approach), the identification of 
biomarkers, or important differentiating phenotypical features, will help to 
stratify patients in a more meaningful manner.  
 
Patient registries 
 
In order to better understand each specific rare disorder better, many groups of 
clinicians and investigators interested in these rare diseases have come 
together to establish registries. In the UK, some examples are NephroS (The 
nephrotic syndrome study)[12], NURTuRE (National Unified Renal 
Translational Research Enterprise)[13], UK Juvenile-onset SLE Cohort Study 
and Repository[14], BCRD (Biologics for Children with Rheumatic Diseases)[5], 
CAPS (Childhood arthritis prospective study)[7] and EPIPEG (Epilepsy in 
infancy: relating phenotype to genotype)[15]. Due to the rarity of each condition, 
it is essential that every patient possible be recruited to ensure that we have a 
good representation of biological samples to analyse. For each study, detailed 
clinical phenotypical data as well as a range of biological samples are collected 
at various time points in the course of the disease. Often these registries have 
data collection integrated into routine clinical care. These produce rich deep 
clinical and biological phenotypic data that will be analysed to generate 
molecular and genetic diagnostic criteria that will reflect underlying disease 
mechanisms. (Figure 1) It is important that in future clinical trials (both 
commercially sponsored and investigator-initiated studies) that associated 
biological samples are collected to enable studies seeking to identify 
biomarkers for disease response or biomarkers associated with development 
of side effects. 
 
A SYSTEMS BIOLOGY APPROACH 
 
Traditionally, science has had a reductionist approach in identifying specific 
perturbations in biological pathways in various disease processes. Although 
this has had some success, particularly for single gene disorders, the regulation 
of biological processes is complex and manifold, and it stands to reason that a 
more holistic systems biology approach would be more successful in identifying 
molecular and genetic diagnostic criteria. Disease onset often has specific 
predisposition factors and/or triggers, be they genetic or environmental, and 
each trigger might result in a cascade of events that affect more than one 
biological network.  
 
The ability to generate vast amounts of data from the ‘omics’ technologies —
genomics, transcriptomics, proteomics, and metabolomics—will enable 
identification of perturbations in biological networks on a systems biology level. 
This has been helped by the increased speed and decreased cost of processing 
these biological samples, and the advancement in bioinformatics so that we 
can better analyse these samples. Simplistically, differences or patterns can be 
compared between two or more clinical states, e.g. recurrence of disease 
versus no recurrence, or response to a therapy, and these biological samples 
are analysed for differences in molecules (e.g. RNA for transcriptomics).  
 
Hood et al[3] propose viewing biology as an information science, which is 
necessary when processing the extensive datasets that traditional data 
architectures are unable to efficiently handle, also known as ‘big data’ (see 
Glossary)[16] that is generated by the ‘omics’. Techniques to analyse this big 
data often involves using ‘machine learning’ algorithms, using either supervised 
or unsupervised learning (see below). Molecules of interest can be checked for 
statistical and biological relevance. They can be grouped, for example by the 
function of these molecules, to check whether there are patterns in ‘networks’ 
(based on previous data available—these can be checked against databases 
e.g. STRING[17]) for a specific disease state. These networks might then point 
to a specific biological mechanism underpinning disease, which would then give 
us clues for the pathophysiology of disease. (Figure 2) Also, we are able to test 
specific molecules within the pathways that might be markedly changed in 
diseased states, and from these, we can determine molecules that might have 
the best specificity and sensitivity for predicting relapses or disease activity, for 
example. Using more traditional laboratory methods, the role of these newly 
identified molecules or biomarkers can then be confirmed.  
 
Genomics 
 
In order to study the genome, most studies were dependent on either 
microarrays or Sanger sequencing. Microarrays require prior knowledge of 
genetic sequences, while Sanger sequencing is expensive and relatively slow. 
Over the last decade, genomics has progressed tremendously due to the 
introduction of Next Generation Sequencing (NGS) technologies.[18]  
 
In traditional Sanger sequencing, DNA is denatured, then annealed to a primer 
of choice, and elongated by the addition of dNTPS (deoxynucleotides—
cytosine, guanine, adenosine and thymine). The substitution of 
dideoxynucleotides (ddNTPs) for deoxynucleotides (dNTPs) for one of these 
bases, e.g. cytosine, results in early termination of the DNA strand at that 
particular ddNTP. These shortened DNA strands can be detected by capillary 
electrophoresis and the position of the base on the strand determined 
according to the length of the strand. This process is laborious and the first big 
improvement was the introduction of fluorescent tags to the ddNTPs, which 
enabled automated detection of different fluorescent tags. NGS (of which there 
are several types) has taken the steps from Sanger sequencing—sequencing, 
electrophoresis and detection—and combined it into an array-based system 
where the reactions are fixed on a solid support on a plate.[18] Millions of 
sequencing reactions can then be processed in parallel, and detection is 
automated. As a result, NGS has resulted in a much higher throughput with 
increased speed and decreased costs, but with a corresponding increase in its 
error rate.[19] As such, Sanger sequencing is used as an established and 
validated technique, to independently check specific sequence changes 
discovered by NGS.  
 
NGS for whole genome sequencing currently costs approximately USD1000 
per person[20], with Illumina’s CEO (one of the largest companies producing 
NGS technologies) predicting that this cost will reduce to USD100 within the 
next 10 years. This will be particularly relevant in the context of diagnosis in 
rare disease. Although the cost and speed of sequencing is rapidly decreasing, 
there are further limitations in the costs of storing and handling this information, 
as well as the analysis and interpretation of such information.  
 
NGS has enabled many research studies to carrying out whole exome 
sequencing (WES) or whole genome sequencing (WGS) (see Glossary). We 
have seen much success in identifying genes for rare disease in NephroS, the 
nephrotic syndrome study. Using NGS technology for whole exome sequencing 
(WES) of patients with steroid-resistant nephrotic syndrome, we have identified 
several new genes causative for steroid-resistant nephrotic syndrome including 
MAGI2 and FAT1[21,22]. This has contributed to the development of the gene 
panel offered by Bristol Genetic Laboratories, which includes 70 genes for 
nephrotic syndrome in a turnaround time of 6 weeks.[23] This has already 
changed clinical practice, with gene panel testing becoming standard for any 
newly diagnosed patient, which potentially avoids the need for renal biopsy, as 
well as avoiding non-specific immunosuppression regimes.[24] In addition, 
combining genomic and clinical profiling of this cohort of children with steroid-
resistant nephrotic syndrome has enabled stratification of patients according to 
aetiology, and hence facilitated appropriate management for individual patients 
e.g. according to high or low risk for recurrence of disease post-renal 
transplantation.[25]  
 
Pharmacogenomics is a field where genetic sequence is used to inform drug 
development, selection and dosing, as well as predict side effects.[26] For 
example, a recent genome wide association study (GWAS) (see Glossary) in 
children with asthma discovered a genetic variation in the platelet-derived-
growth-factor-D (PDGFD) locus that increased the risk of adrenal suppression 
in response to steroid therapy.[27] This finding will potentially enable risk 
stratification of patients for more intensive monitoring of adrenal function, as 
well as encourage use of alternative medications e.g. leukotriene antagonists 
or anti-IgE therapy in these patients where possible.[27]  
 
Cystic fibrosis has seen great success from targeted treatments for specific 
cystic fibrosis variants (see Glossary). Ivacaftor is a CFTR potentiator that 
increases the probability of the channel opening in CFTR gating mutations.[28] 
Lumacaftor is a CFTR corrector that corrects CFTR misprocessing and 
mislocalisation in the p.Phe508del mutation, and in combination with Ivacaftor 
has been shown to reduce pulmonary exacerbations in patients with this 
variant.[29] This is the end result of identifying the correct pathogenic variants, 
understanding the effect of the mutations of the CFTR protein, and using 
targeted therapies to correct this. With increasing understanding of not only 
genomics, but also protein function and localization, other rare diseases can 
learn from the cystic fibrosis story in targeting treatments in genetic diseases.  
 
 
Transcriptomics 
 
Transcriptomics is the study of the entire transcriptome i.e. RNA. This is 
valuable in not only giving us information about coding RNA i.e. RNA which will 
be translated into proteins, but also about noncoding RNA e.g. small interfering 
RNA, microRNA, which have functions in regulating gene expression. 
Transcriptomics currently is carried out via 2 methods—microarray or RNA 
sequencing (RNA-seq). For microarrays, oligomeric probes are fixed on a plate, 
which represent the whole or majority of the known transcriptome. 
Fluorescently labelled transcripts (from the sample of interest) are applied to 
the plate, bind to their complementary probe, and the fluorescent output 
measured. This requires prior knowledge of sequences in order to generate 
appropriate probes, and its dynamic range is limited by the minimal 
fluorescence detectable and fluorescence saturation. RNA-seq involves 
reverse transcription of RNA to complementary DNA, and next generation 
sequencing of complementary DNA. RNA-seq has a higher sensitivity and 
dynamic range, but data analysis is also more complex and labour 
intensive.[30] RNA-seq also requires very little RNA, and can be carried out on 
single cells.[31] This might be particularly relevant for cancer where there is a 
heterogeneous population of cells within a tumour, and is being further 
developed in spatial transcriptomics to visualize transcriptome variation within 
a tissue biopsy sample.[32] 
 
One example where transcriptomics has been highly informative has been in 
lymphocyte transcriptomics in autoimmunity (e.g. SLE, ANCA-associated 
vasculitis) and chronic infections in adults.[33] This has revealed that a pattern 
of CD8 T-cell exhaustion is predictive of reduced relapses in autoimmunity, but 
is associated with poor clearance of chronic infection. This is inversely 
correlated with CD4 co-stimulation. From the data, they identified one marker, 
KAT2B, which could potentially have utility as a surrogate marker of clinical 
outcome in these diseases.[33] This will enable prognostication of clinical 
course, and also has identified potential therapeutic targets to reduce relapse 
in autoimmune disease. Similarly, a landmark study in paediatric SLE 
demonstrated that signature patterns could be derived from lymphocyte 
transcriptomics from children, using longitudinal profiling.[34] This 
‘personalised immunomonitoring’ revealed seven distinct patient groups 
according to disease activity, supported by genotypes. This has clear 
implications for tailored therapies, and trial design.  
 
Proteomics 
 
Proteins essentially control all cellular functions. Proteomics enables the study 
of the entire proteome, the entire protein constituents of cells. Proteins are 
enzymatically broken down e.g. by trypsin into peptides, and these peptides are 
separated by liquid chromatography and detected by mass spectrometry 
according to their size and charge. The abundance of each peptide can be 
measured and these can be mapped to its original protein.  
 
Proteins are complex and are subject to many post-translational modifications 
that determine its three-dimensional structure, cellular localization, biological 
function or whether it is targeted for degradation. Some examples of these post-
translational modifications include phosphorylation, glycosylation, acetylation, 
and ubiquitylation.[35] These modifications lead to a change in mass, which 
can be detected by mass spectrometry. Phosphoproteomics, the study of 
phosphorylation of the proteome, can be valuable in identifying phosphorylation 
events important in the pathogenesis of disease.  
 
Of particular interest is investigation of the plasma proteome for biomarkers. 
However, this has proven challenging due to the complexity of the plasma 
proteome and its inherent variability across the population.[35] Plasma contains 
many high and medium abundance proteins, while biomarkers are more likely 
to be lower abundance proteins. This requires extensive processing of the 
sample e.g. reducing high abundance proteins by immunodepletion and 
fractionation of samples, which increases variability and decreases 
throughput.[36] However, improved techniques now enable detection of greater 
number of proteins, while requiring a smaller starting plasma volume.[36,37] 
The myeloid related protein (MRP) complex 8/14 (S100A8/9, also known as 
calprotectin) has been shown to be marker of response to treatment in children 
with juvenile idiopathic arthritis and also a marker of flare after cessation of 
treatment.[38–40] Improvements in proteomic technology will aid in the search 
for further clinically relevant biomarkers, particularly from easily accessible 
fluids such as plasma.  
 
Using targeted proteomics, a breakthrough study identified the M-type 
phospholipase A2 receptor (PLA2R ) as the antigenic target in a large majority 
of idiopathic membranous nephropathy.[41] This established membranous 
nephropathy as an autoimmune disease, where antibodies against PLA2R are 
found in approximately 70% of patients with idiopathic membranous 
nephropathy. This potentially circumvents the need for kidney biopsy in high 
risk patients who are positive for PLA2R antibodies, and has potential utility in 
predicting treatment outcomes and guiding treatment.[42]   
 
Metabolomics 
 
Metabolomics is the study of a range of metabolites and low molecular weight 
molecules, and is very much a field still in its infancy. The metabolome consists 
of diverse molecules including peptides, lipids, amino acids, nucleic acids, 
carbohydrates, organic acids, vitamins, minerals, food additives, drugs, toxins, 
pollutants and any chemical with a molecular weight less than 2,000 
daltons.[43] The HMDB (Human Metabolome Database) contains in excess of 
40,000 annotated metabolite entries.[43] Detection methods largely use 
chromatography and mass spectrometry, or nuclear magnetic resonance 
spectroscopy; but due to the large variety of molecules in the metabolome, 
these protocols are not standardised and vary from laboratory to laboratory.[44] 
Clinically, we currently use small molecules to diagnose inborn errors of 
metabolism, for example, phenylalanine for phenylketonuria. Our metabolome 
is partially dependent on environmental exposure e.g. via gut microbiota, and 
not solely dependent on our genome. Some of these small molecules might 
change in response to environmental triggers, and metabolomics could have 
utility in understanding pathogenesis of disease that have significant 
environmental triggers.  
 
Early work using metabolomics show that urinary metabolomics at birth could 
be a useful tool to identify premature infants who are at high risk of developing 
chronic lung disease.[45] In addition, a metabolomics approach has also 
identified a metabolic signature early in pregnancy that could potentially predict 
for small for gestational age infants.[46] These studies have identified some 
biologically relevant molecules that might be useful biomarkers, but will require 
validating in larger cohorts.  
 
Data Analysis – developing new tools 
 
Bioinformatics is essential for management of data in modern biology and 
medicine. Bioinformatics is defined as the application of tools of computation 
and analysis to the capture and interpretation of biological data (ref Bayat, BMJ. 
2002 Apr 27; 324(7344): 1018–1022.). It is an interdisciplinary field, which 
harnesses computer science, mathematics, physics, and biology.  
  
The challenge of handling and organising huge amounts of data, and 
interpreting them to identify signature patterns that correspond to disease 
mechanism and behaviour is a considerable one. To complement existing 
bioinformatics approaches, machine learning tools are increasingly being 
developed and utilised, adapting innovations from the world of artificial 
intelligence and computing/mathematics. 
 
There are now a number of state-of-the-art predictors for estimating the 
functional impact of genetic variation in human disease (e.g. Ensembl Variant 
Effect Predictor[47]). Based on data integration algorithms from machine 
learning, tools have been developed for predicting the functional impact of 
single nucleotide variants (SNVs), indels (short insertions and deletions of 
genetic code) and haplo-insufficiency, as examples. These tools use sequence 
and other types of data, such as data drawn from ENCODE (Encyclopedia of 
DNA elements)[48].  
 
Further innovation is being made to integrate broader datasets (e.g. 
transcriptomics, epigenetics). This includes so-called unsupervised learning 
based on Bayesian methods (these maximise the probability of the model given 
the data). The approach is called Latent Process Decomposition (LPD)[49], and 
assesses the structure of a dataset in the absence of knowledge of clinical 
outcome or biological role (hence unsupervised), and has the benefit of being 
more objective. These are mixed membership models, that is, a data sample 
(e.g. derived from a patient) is represented as a combinatorial mixture over 
underlying functional states. This concept is very important in many biomedical 
contexts and contrasts with the hierarchical cluster analysis (dendrograms) 
commonly used by biologists in which data samples or genes are uniquely 
assigned to clusters. Hierarchical clustering restricts the number of dimensions 
that can be taken into account and restricts genes to one cluster, while using 
LPD enables many dimensions to be taken into account and has no such 
restriction on genes. Thus, in the context of cancer, for example, there is 
frequent heterogeneity between cell types present; LPD is able to effectively 
model for underlying causative mechanisms. In recent work, LPD has been 
used to isolate the signature of aggressive prostate cancer against 
nonaggressive disease[50], showing its utility in predicting individual disease 
outcomes. 
 
FUTURE OUTLOOK 
 
We have seen some success in using big data to develop stratified medicine in 
paediatrics, where improved diagnostics has helped to understand 
pathogenesis of disease and stratify patients for targeted therapies. With 
improved understanding of the molecular networks underpinning disease, we 
will be able to identify the best targets for therapy and have a better 
understanding of potential effects of these therapies at a systems level. This 
will enable us to provide individualised therapy for enhanced efficiency and 
safety.  
 
As next generation sequencing technologies progress, we are already seeing 
this coming into clinical use as it becomes more affordable and rapid. For 
example, whole genome sequencing within 24 hours for sick neonates might 
become an important diagnostic tool in diagnosing genetic disorders. With the 
identification of further biomarkers enabling stratification, we will be able to 
target specific patients for clinical trials of new therapies, and reduce the 
number of patients exposed to the ‘wrong’ medications. For rare disease, often 
patient numbers are small, but we can build on previous meta-analyses and the 
information from big data to design trials that are powered appropriately, using 
a Bayesian approach.  
 
This is further becoming a reality in the UK, with two major new paediatric 
projects underway in Stratified Medicine based on existing and ongoing 
collection of patients to specific cohorts, the NURTuRE cohort in renal 
medicine[13], and the CLUSTER Consortium: childhood arthritis and its 
associated uveitis; stratification through endotypes and mechanism to deliver 
benefit[51]. These aim to build and embed new methodologies, alongside 
comprehensive systems biology analyses of clinically deeply phenotyped and 
longitudinally followed patient cohorts. The ultimate aim is re-definition of 
specific rare diseases in these areas according to molecular signatures.  
 
As we become enabled by an increase in our depth of the understanding of the 
molecular mechanisms of disease, we will be increasingly empowered to 
stratify our patients such that the right person receives the right treatment at 
the right time.   
 
  
Figure 1. Stratified medicine approach. Patient registries will enable collection 
of phenotypical data and biological samples. These will be processed and 
analysed using supervised and unsupervised approaches as appropriate. This 
will enable stratification of patients into subgroup according to their molecular 
signature, into more meaningful and biologically relevant subgroups, paving the 
way for clinical trials targeting the correct subgroup. Patients will receive more 
targeted therapies and personalised prognostic information.  
 
Figure 2. A simple overview of the typical workflow involved in sample 
processing using ‘-omics’. Patient samples are processed using ‘omics’ 
technology. Data are often presented using heat maps after hierarchical 
clustering analysis. Heat maps (above adapted from Stubbs et al 2018[52] with 
kind permission of author) give an overall pictorial representation of 
upregulation or downregulation (red being up regulation and blue being down 
regulation in this particular heat map) of various genes, for example. Functional 
protein networks are used to analyse and understand the significance of the 
data. Novel and relevant molecules of interest  are then confirmed by traditional 
laboratory methods. The data will inform and enable novel classifications of 
disease.  
  
 Glossary  
Big data Extensive datasets that traditional data architectures 
are unable to efficiently handle. Characteristics of 
these datasets include increased volume, variety, 
velocity and variability.[16]  
Genetic variants Used to refer to a specific region of the genome that 
differs between 2 genomes. Some variants result in 
phenotypically significant effects that result in illness 
while some are not disease causing. Genetic variants 
are reported clinically as ‘benign’,  ‘likely benign’, 
‘uncertain significance’, ‘likely pathogenic’ and 
‘pathogenic’.[53]  
Genome wide 
association study 
(GWAS) 
Study of genetic variants (typically SNPs—single 
nucleotide polymorphisms) and their associations with 
disease. Usually, the SNPs are identified using SNP 
microarrays.  
Mutation Permanent alteration in DNA sequence.   
Whole exome 
sequencing (WES) 
Sequencing of the entire exome i.e. the protein 
coding area of DNA that comprises about 1% of the 
total genome.  
Whole genome 
sequencing 
(WGS) 
Sequencing of the entire genome, including intronic 
regions.   
 
  
 Contributors: WYD wrote the first draft, revised the manuscript and approved 
the final version. AVR and MAS conceived the work, edited the manuscript and 
approved the final version. MWB edited the manuscript and approved the final 
version.  
 
Funding: WYD is funded by a Kidney Research UK Clinical Research 
Fellowship.  
 
Competing interests: MAS has external consultancy roles with UCB, Retrophin 
and Pfizer.  
AVR has received Speaker fees/Consultancy for Abbvie, Eli Lilly, UCB and 
SOBI. 
 
 
 
 
REFERENCES 
1  Day S, Coombes RC, McGrath-Lone L, et al. Stratified, precision or 
personalised medicine? Cancer services in the ‘real world’ of a London 
hospital. Sociol Health Illn 2017;39:143–58. doi:10.1111/1467-
9566.12457 
2  Graham, Ellen (Medicines, Diagnostics and Personalised Medicine Unit, 
Medical Directorate NE. IMPROVING OUTCOMES THROUGH 
PERSONALISED MEDICINE Working at the cutting edge of science to 
improve patients’ lives. 2016.  
3  Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21st 
century through systems approaches. Biotechnol J 2012;7:992–1001. 
doi:10.1002/biot.201100306 
4  Registry (RaDaR) | Rare Renal. http://rarerenal.org/radar-registry/ 
(accessed 27 Mar 2018). 
5  Biologics for Children with Rheumatic Diseases. 
http://www.bcrdstudy.org/default.asp (accessed 17 May 2018). 
6  British Society for Paediatric and Adolescent Rheumatology Etanercept 
Registry. 
https://www.rheumatology.org.uk/Knowledge/Registers/Juvenile-
Idiopathic-Arthritis-register (accessed 17 May 2018). 
7  Childhood Arthritis Prospective Study (CAPS). https://www.caps-
childhoodarthritisprospectivestudy.co.uk/ (accessed 17 May 2018). 
8  The 100,000 Genomes Project | Genomics England. 
https://www.genomicsengland.co.uk/the-100000-genomes-project/ 
(accessed 4 Apr 2018). 
9  Field M, Boat T, editors. Profile of Rare Diseases. In: Rare Diseases 
and Orphan Products: Accelerating Research and Development. 
Washington (DC): : National Academies Press (US) 2010. 41–72. 
10  European Medicines Agency - Overview - Orphan designation. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general
/general_content_000029.jsp&mid=WC0b01ac0580b18a41 (accessed 
27 Mar 2018). 
11  What is a rare disease? | Great Ormond Street Hospital Children’s 
Charity. https://www.gosh.org/what-we-do/research/zayed-centre-
research-rare-disease-children/rare-diseases/what-rare-disease 
(accessed 27 Mar 2018). 
12  NephroS Study Information | Rare Renal. http://rarerenal.org/clinician-
information/nephrotic-syndrome-clinician-information/nephros-study/ 
(accessed 20 May 2018). 
13  NURTuRE – A unique kidney biobank. https://www.nurturebiobank.org/ 
(accessed 17 May 2018). 
14  UK JSLE Study Group - Institute of Translational Medicine - University 
of Liverpool. https://www.liverpool.ac.uk/translational-
medicine/research/ukjsle/ (accessed 17 May 2018). 
15  EPIPEG – Epilepsy in infancy: relating phenotype to genotype. 
http://epipeg.co.uk/ (accessed 17 May 2018). 
16  NIST Big Data Public Working Group. NIST Special Publication 1500-1 
- NIST Big Data Interoperability Framework: Volume 1, Definitions. 
NIST Spec Publ 2015;1:32. doi:http://dx.doi.org/10.6028/NIST.SP.1500-
1 
17  STRING: functional protein association networks. https://string-db.org 
18  Metzker ML. Sequencing technologies the next generation. Nat Rev 
Genet 2010;11:31–46. doi:10.1038/nrg2626 
19  Schirmer M, Ijaz UZ, D’Amore R, et al. Insight into biases and 
sequencing errors for amplicon sequencing with the Illumina MiSeq 
platform. Nucleic Acids Res 2015;43. doi:10.1093/nar/gku1341 
20  DNA Sequencing Costs: Data - National Human Genome Research 
Institute (NHGRI). https://www.genome.gov/sequencingcostsdata/ 
(accessed 21 May 2018). 
21  Bierzynska A, Soderquest K, Dean P, et al. MAGI2 Mutations Cause 
Congenital Nephrotic Syndrome. J Am Soc Nephrol 2017;28:1614–21. 
doi:10.1681/ASN.2016040387 
22  Gee HY, Sadowski CE, Aggarwal PK, et al. FAT1 mutations cause a 
glomerulotubular nephropathy. Nat Commun 2016;7:10822. 
doi:10.1038/ncomms10822 
23  Roberts E, Williams M, Watson E. Renal panel for Steroid Resistant 
Nephrotic Syndrome (SRNS), Alport syndrome and rare inherited renal 
disease.  
24  Sen ES, Dean P, Yarram-Smith L, et al. Clinical genetic testing using a 
custom-designed steroid-resistant nephrotic syndrome gene panel: 
analysis and recommendations. J Med Genet 2017;54:795–804. 
doi:10.1136/jmedgenet-2017-104811 
25  Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical 
profiling of a national nephrotic syndrome cohort advocates a precision 
medicine approach to disease management. Kidney Int 2017;91:937–
47. doi:10.1016/j.kint.2016.10.013 
26  Feero WG, Guttmacher AE. Genomics, personalized medicine, and 
pediatrics. Acad Pediatr 2013;14:14–22. 
doi:10.1016/j.acap.2013.06.008 
27  Hawcutt DB, Francis B, Carr DF, et al. Susceptibility to corticosteroid-
induced adrenal suppression: a genome-wide association study. Lancet 
Respir Med 2018;0. doi:10.1016/S2213-2600(18)30058-4 
28  Yu H, Burton B, Huang C-J, et al. Ivacaftor potentiation of multiple 
CFTR channels with gating mutations. J Cyst Fibros 2012;11:237–45. 
doi:10.1016/j.jcf.2011.12.005 
29  Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–Ivacaftor in 
Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl 
J Med 2015;373:220–31. doi:10.1056/NEJMoa1409547 
30  Lowe R, Shirley N, Bleackley M, et al. Transcriptomics technologies. 
PLoS Comput Biol 2017;13:1–23. doi:10.1371/journal.pcbi.1005457 
31  Park J, Shrestha R, Qiu C, et al. Single-cell transcriptomics of the 
mouse kidney reveals potential cellular targets of kidney disease. 
Science 2018;360:758–63. doi:10.1126/science.aar2131 
32  Vickovic S, Magnusson J, Giacomello S, et al. Visualization and 
analysis of gene expression in tissue sections by spatial 
transcriptomics. 2016;353. 
33  Mckinney EF, Lee JC, Jayne DRW, et al. T-cell exhaustion, co-
stimulation and clinical outcome in autoimmunity and infection. 
Published Online First: 2015. doi:10.1038/nature14468 
34  Banchereau R, Hong S, Cantarel B, et al. Personalized 
Immunomonitoring Uncovers Molecular Networks that Stratify Lupus 
Patients. Cell 2016;165:551–65. doi:10.1016/j.cell.2016.03.008 
35  Aebersold R, Mann M. Mass-spectrometric exploration of proteome 
structure and function. Nature 2016;537:347–55. 
doi:10.1038/nature19949 
36  Geyer PE, Kulak NA, Pichler G, et al. Plasma Proteome Profiling to 
Assess Human Health and Disease. Cell Syst 2016;2:185–95. 
doi:10.1016/j.cels.2016.02.015 
37  Keshishian H, Burgess MW, Gillette MA, et al. Multiplexed, Quantitative 
Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel 
Candidates for Early Myocardial Injury. Mol Cell Proteomics 
2015;14:2375–93. doi:10.1074/mcp.M114.046813 
38  Anink J, Van Suijlekom-Smit LWA, Otten MH, et al. MRP8/14 serum 
levels as a predictor of response to starting and stopping anti-TNF 
treatment in juvenile idiopathic arthritis. Arthritis Res Ther 2015;17:200. 
doi:10.1186/s13075-015-0723-1 
39  Gerss J, Roth J, Holzinger D, et al. Phagocyte-specific S100 proteins 
and high-sensitivity C reactive protein as biomarkers for a risk-adapted 
treatment to maintain remission in juvenile idiopathic arthritis: a 
comparative study. Ann Rheum Dis 2012;71:1991–7. 
doi:10.1136/annrheumdis-2012-201329 
40  Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate Withdrawal at 
6 vs 12 Months in Juvenile Idiopathic Arthritis in 
Remission&lt;subtitle&gt;A Randomized Clinical Trial&lt;/subtitle&gt; 
JAMA 2010;303:1266. doi:10.1001/jama.2010.375 
41  Beck LH, Bonegio RGB, Lambeau G, et al. M-Type Phospholipase A 2 
Receptor as Target Antigen in Idiopathic Membranous Nephropathy. N 
Engl J Med 2009;361:11–21. doi:10.1056/NEJMoa0810457 
42  Hofstra JM, Wetzels JFM. Phospholipase A2 receptor antibodies in 
membranous nephropathy: unresolved issues. J Am Soc Nephrol 
2014;25:1137–9. doi:10.1681/ASN.2014010091 
43  Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0—The Human 
Metabolome Database in 2013. Nucleic Acids Res 2012;41:D801–7. 
doi:10.1093/nar/gks1065 
44  Clish CB. Metabolomics: an emerging but powerful tool for precision 
medicine. Cold Spring Harb Mol case Stud 2015;1:a000588. 
doi:10.1101/mcs.a000588 
45  Fanos V, Cristina Pintus M, Lussu M, et al. Urinary metabolomics of 
bronchopulmonary dysplasia (BPD): preliminary data at birth suggest it 
is a congenital disease. J Matern Neonatal Med 2014;27:39–45. 
doi:10.3109/14767058.2014.955966 
46  Horgan RP, Broadhurst DI, Walsh SK, et al. Metabolic Profiling 
Uncovers a Phenotypic Signature of Small for Gestational Age in Early 
Pregnancy. J Proteome Res 2011;10:3660–73. doi:10.1021/pr2002897 
47  McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. 
Genome Biol 2016;17:122. doi:10.1186/s13059-016-0974-4 
48  ENCODE: Encyclopedia of DNA Elements – ENCODE. 
https://www.encodeproject.org/ (accessed 21 May 2018). 
49  Rogers S, Girolami M, Campbell C, et al. The Latent Process 
Decomposition of cDNA Microarray Data Sets. IEEE/ACM Trans 
Comput Biol Bioinforma 2005;2:143–56. doi:10.1109/TCBB.2005.29 
50  Luca B-A, Brewer DS, Edwards DR, et al. DESNT: A Poor Prognosis 
Category of Human Prostate Cancer. Eur Urol Focus 2017;0. 
doi:10.1016/j.euf.2017.01.016 
51  Research - Research - Medical Research Council. 
https://mrc.ukri.org/research/initiatives/stratified-medicine/research/ 
(accessed 20 May 2018). 
52  Stubbs FE, Birnie MT, Biddie SC, et al. SKOV3 cells containing a 
truncated ARID1a protein have a restricted genome-wide response to 
glucocorticoids. Mol Cell Endocrinol 2018;461:226–35. 
doi:10.1016/j.mce.2017.09.018 
53  Richards S, Aziz N, Bale S, et al. Standards and guidelines for the 
interpretation of sequence variants: a joint consensus recommendation 
of the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology. Genet Med 2015;17:405–23. 
doi:10.1038/gim.2015.30 
 
